Results 221 to 230 of about 219,955 (289)

Herpesviridae Reactivation and Therapeutic Outcomes in Patients with Ulcerative Colitis Treated with Tofacitinib. [PDF]

open access: yesJ Clin Med
Harnik S   +13 more
europepmc   +1 more source

Multifaceted burden of short bowel syndrome for patients and caregivers: The landmark survey

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Background Short bowel syndrome is a debilitating condition often requiring long‐term parenteral support to maintain hydration, nutrition, and survival. Methods As part of the noninterventional, cross‐sectional Landmark Survey study, we evaluated burdens associated with short bowel syndrome and parenteral support dependency from patient and ...
Jenny E. Harrison   +11 more
wiley   +1 more source

Rethinking colitis: MrgprD puts macrophages in the driver's seat†

open access: yesThe Journal of Pathology, EarlyView.
Abstract There is increasing evidence to suggest that dysregulated macrophages play an important role in the promotion and maintenance of inflammatory bowel disease (IBD), yet the underlying mechanisms remain unclear. A recent study published by Lv, Xia, Qiao et al in The Journal of Pathology investigated the role of Mas‐related G protein‐coupled ...
Kolja Pocha, Konstantin Bräutigam
wiley   +1 more source

Characteristics, properties and limitations of per‐ or polyfluoroalkyl substances (PFASs) and fluoropolymers

open access: yesPolymer International, EarlyView.
An overview and categorization of man‐made per‐ or polyfluoroalkyl substances (PFASs) including low‐molar‐mass and high‐molar‐mass fluorochemicals, and their international regulations is presented. Though certain PFASs are toxic, bioaccumulative and cross the human cellular membranes, others, such as fluoropolymers, are safe, reliable and involved in ...
Bruno Améduri
wiley   +1 more source

Assessment of Bowel Urgency in Ulcerative Colitis: Current Measures and Future Directions. [PDF]

open access: yesGastro Hep Adv
Dubinsky M   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy